Impact of neoadjuvant durvalumab (D) on tumor microenvironment (TME) features and their association with event-free survival (EFS) in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial.
Randomized trial shows how neoadjuvant durvalumab affects tumor microenvironment and event-free survival in resectable NSCLC, indicating broader implications for treatment.
Key Points
This research aims to investigate the influence of neoadjuvant durvalumab on tumor microenvironment features and their correlation with event-free survival in patients with resectable NSCLC.
Double-blind placebo-controlled study (NCT03800134)
Adults with treatment-naïve resectable NSCLC were randomized to receive neoadjuvant platinum-based chemotherapy with durvalumab or placebo.
Transcriptional analyses conducted on tumor samples collected at baseline and surgery to classify tumor microenvironment features.
Three phenotypic clusters based on TME features were identified at baseline: immune desert (C1), immune suppressed (C2), and immune activated (C3).
Event-free survival at 36 months was significantly different across clusters: C1 (27.8%), C2 (55.7%), and C3 (77.2%).
Neoadjuvant durvalumab was associated with a higher proportion of patients converting to immune-activated phenotypes after treatment.